Journal article
Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging
Andrew Neal, Bradford A Moffat, Joel M Stein, Ravi Prakash Reddy Nanga, Patricia Desmond, Russell T Shinohara, Hari Hariharan, Rebecca Glarin, Katharine Drummond, Andrew Morokoff, Patrick Kwan, Ravinder Reddy, Terence J O'Brien, Kathryn A Davis
NEUROIMAGE-CLINICAL | ELSEVIER SCI LTD | Published : 2019
Abstract
INTRODUCTION: Diffuse gliomas are incurable malignancies, which undergo inevitable progression and are associated with seizure in 50-90% of cases. Glutamate has the potential to be an important glioma biomarker of survival and local epileptogenicity if it can be accurately quantified noninvasively. METHODS: We applied the glutamate-weighted imaging method GluCEST (glutamate chemical exchange saturation transfer) and single voxel MRS (magnetic resonance spectroscopy) at 7 Telsa (7 T) to patients with gliomas. GluCEST contrast and MRS metabolite concentrations were quantified within the tumour region and peritumoural rim. Clinical variables of tumour aggressiveness (prior adjuvant therapy and ..
View full abstractRelated Projects (4)
Grants
Awarded by National Institutes of Health
Awarded by NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Funding Acknowledgements
This work was supported by National Institutes of Health grant P41 EB015893 (NIBIB), K23-NS073801-01 and the Royal Melbourne Hospital Neuroscience Foundation. Dr. Andrew Neal was supported by an Australian Government Research Training Program Scholarship, and a Miriam Greenfield Research Establishment Fellowship. 7 T scanning was supported by the Melbourne node of the Australian National Imaging Facility supported under the NCRIS program. We also acknowledge support from the Farber and Thornton Foundations.